Optimization of lipidsiting therapy in patients with ischemic stroke and type 2 diabetes mellitus

Author:
L.A. Shchepanevich, Yu.A. Nikolaev, N.A. Dolgova

FGBNU "Research Institute of Experimental and Clinical Medicine", Novosibirsk

Place of publication:
JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2, 2016

Abstract:
The aim of the study was to determine the efficacy of Mexidol therapy to optimize secondary prevention of vascular events by influencing vascular-platelet hemostasis parameters and blood lipid profile in patients with a history of ischemic stroke (IS) and type 2 diabetes mellitus (T2DM). Material and Methods. Serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured; concentrations of 4-platelet factor (4PPF), β-thromboglobulin (βTG), and von Willebrand factor were determined in 68 patients with IS and T2DM. Dynamic monitoring of the studied parameters (days 1 and 21, months 3 and 6 from the onset of IS) was performed during Mexidol therapy. Results and conclusion. Long-term therapy with Mexidol provides additional opportunities for normalizing the blood lipid spectrum and optimizing secondary prevention of vascular events in patients with ischemic stroke and type 2 diabetes.

Actual

Actual

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com